On May 26, 2020, the FDA approved Amivas’ artesunate for injection to treat severe malaria in adult and pediatric patients. Treatment of severe malaria with intravenous (IV) artesunate should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.

There has been no FDA-approved drug for treatment of severe malaria in the U.S.. since the marketing of quinine was discontinued by the manufacturer in March 2019.